AAA
VRNA

Affinity Asset Advisors’s Verona Pharma VRNA Stock Holding History

Affinity Asset Advisors’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-625,000
Closed -$66.7M – 123
2025
Q3 		$66.7M Buy
625,000
+15,000
+2% +$1.57M 5.81% 1
2025
Q2 		$57.7M Sell
610,000
-5,000
-0.8% -$370K 7.88% 1
2025
Q1 		$39M Sell
615,000
-45,000
-7% -$2.69M 3.73% 6
2024
Q4 		$30.7M Buy
660,000
+10,000
+2% +$375K 4.11% 7
2024
Q3 		$18.7M Sell
650,000
-50,000
-7% -$1.23M 2.55% 12
2024
Q2 		$10.1M Sell
700,000
-117,833
-14% -$1.72M 1.17% 26
2024
Q1 		$13.2M Buy
817,833
+254,009
+45% +$4.39M 1.63% 17
2023
Q4 		$11.2M Buy
563,824
+195,495
+53% +$2.89M 2.05% 18
2023
Q3 		$6M Sell
368,329
-79,338
-18% -$1.53M 1.69% 21
2023
Q2 		$9.46M Sell
447,667
-5,154
-1% -$110K 3.31% 11
2023
Q1 		$9.09M Buy
452,821
+140,323
+45% +$3.03M 3% 9
2022
Q4 		$8.17M Sell
312,498
-37,502
-11% -$499K 3.2% 8
2022
Q3 		$3.58M Buy
+350,000
New +$2.95M 1% 31

Other funds holding VRNA

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Affinity Asset Advisors's VRNA Position: Q4 2025 in Review

Affinity Asset Advisors sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 625,000 shares — an estimated $66.7M sold.

Affinity Asset Advisors first reported a position in VRNA in Q3 2022 and held it in 13 quarters. The position peaked at $66.7M in Q3 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.

  • Affinity Asset Advisors reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
  • Affinity Asset Advisors sold 625,000 Verona Pharma shares in Q4 2025, an estimated $66.7M.
  • Affinity Asset Advisors first reported a position in Verona Pharma in Q3 2022 and held it in 13 quarters.
  • Affinity Asset Advisors's Verona Pharma position peaked at $66.7M in Q3 2025.
  • 1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.

Based on Affinity Asset Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.